CJMB · CALLAN JMB INC.

Callan JMB Inc. reported its full-year 2025 financial results, showing a challenging year with revenue declining 12.8% to $5.72 million from $6.56 million in 2024. The company attributed this decrease to reduced demand for emergency preparedness services from certain state and local governments. While gross profit decreased to $2.10 million from $2.56 million, the more significant impact came from SG&A expenses, which nearly doubled to $8.60 million from $4.84 million. Management cited professional fees related to the company's initial public offering and transition to a public entity, along with increased information technology support costs, as the primary drivers of this expense increase. The combination of lower revenue and higher operating expenses resulted in an operating loss of $7.03 million, significantly wider than the $2.27 million loss in 2024. Net loss followed a similar pattern, expanding to $7.97 million from $2.29 million. Despite these financial challenges, the company highlighted several strategic initiatives aimed at future growth. These include a manufacturing oversight agreement with Attune Biotech, a joint venture with Revival Health, expansion into India through Callan JMB Services (India) Private Limited, and strengthened government relationships through contract extensions in Chicago and Oregon. The company also noted it had raised capital through its IPO and an ELOC facility, ending the year with $2.13 million in cash and cash equivalents. Management emphasized their focus on strengthening core infrastructure, scaling readiness capabilities, and advancing strategic growth initiatives in healthcare and food logistics sectors for the remainder of 2026.